DAX23.881 +0,6%ESt505.530 +0,4%Top 10 Crypto15,85 -0,4%Dow46.398 +0,2%Nas22.660 +0,3%Bitcoin96.982 -0,5%Euro1,1742 ±0,0%Öl67,06 -0,9%Gold3.861 +0,1%
Beliebte Suche
DAX 40 Ölpreis Euro - Dollar Bitcoin - Euro Goldpreis
Meistgesucht
DroneShield A2DMAA Rheinmetall 703000 Lufthansa 823212 RENK RENK73 Wolfspeed A41JEH NVIDIA 918422 HENSOLDT HAG000 Alibaba A117ME Novo Nordisk A3EU6F Tesla A1CX3T Siemens Energy ENER6Y BYD A0M4W9 Deutsche Telekom 555750 Mercedes-Benz Group (ex Daimler) 710000 Commerzbank CBK100
Alle Aktien für 0 Euro (zzgl. Spreads) handeln mit finanzen.net zero. Hier informieren
Heute im Fokus
US-Shutdown droht: US-Börsen schließen dennoch höher -- DAX letztlich fester -- CoreWeave, Meta, Lufthansa, Continental, Alibaba, Tilray, Clara Technologies, Wolfspeed, Firefly, Etsy, Shopify im Fokus
Top News
3. Quartal 2025: So bewegten sich die DAX-Aktien im vergangenen Quartal 3. Quartal 2025: So bewegten sich die DAX-Aktien im vergangenen Quartal
Tesla-Aktie vor erneutem Schub: Überraschen die Auslieferungszahlen positiv? Tesla-Aktie vor erneutem Schub: Überraschen die Auslieferungszahlen positiv?
Suche...
Login
ODER

Neu auf finanzen.net?

Kostenfrei registrieren und Vorteile nutzen

Übersicht Wertpapierdepots Musterdepots Watchlists Meine News Newsletter Forum Trading Desk Apps Social Media Podcasts
Profil

CSL Aktie

Kaufen
Verkaufen
CSL Aktien-Sparplan
55,00 EUR -0,50 EUR -0,90 %
BMN
CSL jetzt ohne Ordergebühren (zzgl. Spreads) handeln beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 11/2024)
Smartphone
KGV25,35Div. Rendite1,73%
WKN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

WKNA115DF

ISIN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

ISINUS12637N2045

Symbol wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

SymbolCSLLY

CSL Aktien News

DatumMeistgelesen
PR NewswireCSL Vifor and Travere Therapeutics Recognize Updated KDIGO Clinical Practice Guidelines for IgA Nephropathy
PR NewswireCSL Vifor and Travere Therapeutics Recognize Updated KDIGO Clinical Practice Guidelines for IgA Nephropathy
Business TimesAustralian biotech giant CSL to spin off vaccine unit Seqirus, cut 15% of workforce
Wer­bungCSL-Aktie für 0 Euro (zzgl. Spreads) handeln bei finanzen.net zero
PR NewswireHealth Canada Has Authorized CSL's ANDEMBRY® (garadacimab) as Once-Monthly Treatment for Hereditary Angioedema (HAE)
PR NewswireU.S. Food and Drug Administration Approves CSL's ANDEMBRY® (garadacimab-gxii), the Only Prophylactic Hereditary Angioedema (HAE) Treatment Targeting Factor XIIa with Once-Monthly Dosing for All Pa...
PR NewswireEngland's NICE recommends FILSPARI® (sparsentan) as a treatment option for IgA nephropathy
PR NewswireEngland's NICE recommends FILSPARI® (sparsentan) as a treatment option for IgA nephropathy
PR NewswireEngland's NICE recommends FILSPARI® (sparsentan) as a treatment option for IgA nephropathy
PR NewswireEngland's NICE recommends FILSPARI® (sparsentan) as a treatment option for IgA nephropathy
PR NewswireEngland's NICE recommends FILSPARI® (sparsentan) as a treatment option for IgA nephropathy
PR NewswireCSL Vifor and Travere Therapeutics announce standard EU approval for FILSPARI® in IgA Nephropathy
PR NewswireCSL Vifor and Travere Therapeutics announce standard EU approval for FILSPARI® in IgA Nephropathy
PR NewswireCSL Vifor and Travere Therapeutics announce standard EU approval for FILSPARI® in IgA Nephropathy
PR NewswireCSL Vifor and Travere Therapeutics announce standard EU approval for FILSPARI® in IgA Nephropathy
PR NewswireCSL Vifor and Travere Therapeutics announce standard EU approval for FILSPARI® in IgA Nephropathy
ZacksCarlyle Secured Lending Announces Completion of Merger With CSL III
PR NewswireCSL Receives Approval in Japan for ANDEMBRY® (garadacimab) Subcutaneous (S.C.) Injection 200mg Pens, a Novel Human Anti-Activated Factor XII Monoclonal Antibody for the Prevention of Acute Attacks...
PR NewswireEuropean Commission Approves CSL and Arcturus Therapeutics' KOSTAIVE®, the First Self-amplifying mRNA COVID-19 Vaccine
PR NewswireEuropean Commission Approves CSL's ANDEMBRY® (garadacimab) for the Prevention of Recurrent Attacks of Hereditary Angioedema (HAE)
BenzingauniQure/ CSL Behring's Hemophilia Gene Therapy Shows Sustained Efficacy and Safety At Four Years
PR NewswireCSL Behring's Gene Therapy HEMGENIX® (etranacogene dezaparvovec-drlb) Four Years Post-Infusion Data Continue to Show Sustained Efficacy and Safety in Adults with Hemophilia B
PR NewswireCSL Receives Positive CHMP Opinion for Garadacimab in Hereditary Angioedema (HAE)
PR NewswireNew Data Presented at IDWeek 2024 Show Adjuvanted and High-Dose Influenza Vaccines are Comparable in Protecting Adults 65 Years of Age and Older Against Seasonal Influenza
PR NewswireCSL Vifor and Travere Therapeutics Announce Swissmedic approval of FILSPARI® (sparsentan) for the treatment of IgA Nephropathy
PR NewswireCSL Vifor and Travere Therapeutics Announce Swissmedic approval of FILSPARI® (sparsentan) for the treatment of IgA Nephropathy
PR NewswireCSL Vifor and Travere Therapeutics Announce Swissmedic approval of FILSPARI® (sparsentan) for the treatment of IgA Nephropathy
PR NewswireCSL Vifor and Travere Therapeutics Announce Swissmedic approval of FILSPARI® (sparsentan) for the treatment of IgA Nephropathy
PR NewswireCSL Vifor and Travere Therapeutics Announce Swissmedic approval of FILSPARI® (sparsentan) for the treatment of IgA Nephropathy
PR NewswireCSL Seqirus Presents Data at IDWeek 2024 Highlighting the Urgent Need to Increase Influenza Vaccination Rates and the Benefits of Cell-Based Influenza Vaccines
BenzingaGSK, Sanofi, And CSL Secure US Government Fund To Boost Bird Flu Vaccine Production: Report
PR NewswireCSL Seqirus, a Global Leader in Pandemic Preparedness, Announces Sixth BARDA Award in Response to Avian Influenza
PR NewswireCSL Seqirus Presents Real-World Evidence at OPTIONS XII Conference Highlighting Effectiveness of Influenza Vaccinations
PR NewswireSelf-Amplifying mRNA COVID-19 Vaccine Demonstrates Superior Immune Response Compared with mRNA Vaccine at 12 Months Post-Vaccination
PR NewswireCSL Seqirus, a Global Leader in Pandemic Preparedness, Announces Fifth BARDA Award in Response to Avian Influenza Outbreak
PR NewswireVeltassa® (patiromer) approved in Japan for the treatment of adults with hyperkalemia
PR NewswireVeltassa® (patiromer) approved in Japan for the treatment of adults with hyperkalemia
PR NewswireVeltassa® (patiromer) approved in Japan for the treatment of adults with hyperkalemia
PR NewswireVeltassa® (patiromer) approved in Japan for the treatment of adults with hyperkalemia
PR NewswireVeltassa® (patiromer) approved in Japan for the treatment of adults with hyperkalemia
PR NewswireJapan's Ministry of Health, Labor and Welfare Approves CSL and Arcturus Therapeutics' Updated Self-amplifying mRNA COVID-19 Vaccine for Protection against JN.1 Strain, to be Distributed in Japan b...

CSL News

CSL News: auf dieser Seite finden Sie alle CSL News und Nachrichten zur CSL Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch CSL News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um CSL News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.